Docetaxel is under clinical development by Meridian Laboratories and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs for Sarcomas have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Docetaxel is an antineoplastic agent and anti-mitotic agent. It is formulated as injectable solution for intravenous route of administration. Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, hormone refractory) metastatic prostate cancer in combination with prednisone, patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction in combination with cisplatin and fluorouracil, locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Docetaxel (ML061, captisol-enabled docetaxel) is under development for the treatment of liver cancer, sarcoma and hemolytic toxicity. The drug candidate is a lyophilized powder formulation administered through injection. It is a reformulation of taxotere in captisol that eliminates Polysorbate 80 and its associated Black Box side effects. The drug candidate is developed based on captisol technology.
For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.